thioridazine has been researched along with erythromycin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barreca, ML; Cannalire, R; Cecchetti, V; Couto, I; Felicetti, T; Machado, D; Manfroni, G; Massari, S; Sabatini, S; Santos Costa, S; Tabarrini, O; Viveiros, M | 1 |
| Schoenholtz, JC | 1 |
| Crumb, WJ | 1 |
| Butler, AS; Dempsey, CE; El Harchi, A; Hancox, JC; Zhang, Y | 1 |
1 review(s) available for thioridazine and erythromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for thioridazine and erythromycin
| Article | Year |
|---|---|
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
Topics: Anti-Bacterial Agents; Drug Design; Genistein; Mycobacterium avium; Quinolones | 2017 |
Oral erythromycin and the risk of sudden death.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Cytochrome P-450 Enzyme Inhibitors; Death, Sudden, Cardiac; Drug Interactions; Electrocardiography; Erythromycin; Haloperidol; Humans; Thioridazine | 2005 |
Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.
Topics: Binding Sites; Carrier Proteins; Clotrimazole; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Membrane Potentials; Potassium Channel Blockers; Terfenadine; Thioridazine; Transfection; Tripartite Motif Proteins | 2014 |
The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine.
Topics: Antipsychotic Agents; Binding Sites; ERG1 Potassium Channel; Erythromycin; HEK293 Cells; Histamine H1 Antagonists, Non-Sedating; Humans; Inhibitory Concentration 50; Macrolides; Patch-Clamp Techniques; Terfenadine; Thioridazine | 2020 |